J&J says its lung cancer drug combination keeps people alive longer
“Key Points: Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year longer than AstraZeneca’s Tagrisso in a clinical trial. J&J is trying to supplant AstraZeneca’s blockbuster Tagrisso, a once-daily pill that has transformed the treatment of non-small cell lung cancer with EGFR mutations. It remains to be seen how many doctors will adopt the treatment.”
Breaking Down Silos: CU Cancer Center Program Casts a Wide Net for Lung Cancer Research
“Some of the University of Colorado Cancer Center’s foremost scientists are investigating ways to apply their groundbreaking research in various fields to lung cancer with funding and collaborative support from the cancer center’s Thoracic Oncology Research Initiative (TORI).”
Lung Cancer Research Foundation (LCRF) Announces Request for Proposals in Collaboration with Bayer Pharmaceuticals
“NEW YORK, Jan. 7, 2025 /PRNewswire/ — Today, the Lung Cancer Research Foundation, in collaboration with Bayer Pharmaceuticals, announced submissions are being accepted for the $500,000, two-year award, titled LCRF|Bayer Research Award on Innovative Therapeutic Strategies to Treat Lung Cancers Harboring HER2 Mutations and/or Other HER2 Alterations.”
FDA Grants Fast Track Designation to Vergent Bioscience’s Novel Agent for Visualizing Solid Tumors During Lung Cancer Surgeries
“The FDA has granted Fast Track designation to Vergent Bioscience’s VGT-309, an injectable tumor-targeted fluorescent imaging agent designed to aid surgeons in visualizing tumors, lymph nodes, and positive surgical margins during lung cancer surgeries. According to the company, the decision by the FDA was based on positive safety, tolerance, and enhanced tumor visualization results in lung cancer patients.”
FDA grants priority review to oral non-small cell lung cancer drug
“The FDA granted priority review to a new drug application for sunvozertinib as an oral treatment for certain patients with locally advanced or metastatic non-small cell lung cancer, according to a press release from Dizal.”
New Test Predicts Survival in Early-Stage Lung Cancer Better than Current Methods
“Researchers at the Francis Crick Institute and University College London (UCL) Cancer Institute have demonstrated that a test called the ORACLE can better predict clinical outcomes for patients with early-stage lung cancer than current methods. The findings, published in Nature Cancer, could allow doctors to identify which patients with stage I lung cancer would benefit from chemotherapy and surgery—information that current clinical standard testing is not able to provide.”
Lung cancer trial reveals 40% drop in deaths using biomarker testing
“Groundbreaking research from the University of St Andrews School of Medicine has found that biomarker testing in individuals at risk of lung cancer led to a major reduction in deaths. This study, conducted with 12,000 smokers and ex-smokers, demonstrates how biomarkers—measurable indicators of biological changes—can identify individuals at high risk of lung cancer, leading to earlier detection and significantly improved outcomes.”
Primary Lung Tumor SBRT Followed by Mediastinal Chemoradiotherapy in Locally Advanced NSCLC
“In a phase II trial reported in The Lancet Oncology, Heinzerling et al found that primary lung tumor stereotactic body radiotherapy (SBRT) followed by concurrent mediastinal chemoradiotherapy (with or without adjuvant immunotherapy) was associated with activity in patients with locally advanced non–small cell lung cancer (NSCLC).”
Factors Associated With Suicide Among Patients With Lung Cancer in the United States: A Retrospective Cohort Study Based on Surveillance, Epidemiology, and End Results (SEER) Data
“Conclusion: A lung cancer diagnosis is associated with a higher risk of suicide compared to the general population and patients with other cancer types. We suggest that screening for distress, using the National Comprehensive Cancer Network (NCCN) distress screening tool, and depression at regular intervals in patients with lung cancer is imperative to mitigate the non-cancer loss of life.”
Video
Project hopes to boost detection of lung cancer
“Nevada is launching a four-year lung cancer screening program, supported by a $7 million grant, to address its low screening rates and reduce cancer-related deaths. Inspired by Kentucky’s success, the initiative aims to normalize screening through primary care, improve education, and reduce stigma surrounding lung cancer. The long-term goal is to develop a scalable model for nationwide use, improving survivorship and early detection.”
Supreme Court to weigh reinstating Obamacare care requirements struck down by lower court
“Services and medications that might not be covered under the ruling include statins to prevent heart disease, lung cancer screening, HIV prevention, as well as medications to lower the risk of breast cancer for high-risk women, the group found.”
